D. Boral Capital Reaffirms Buy Rating for Kairos Pharma (NYSEAMERICAN:KAPA)
Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a report released on Wednesday,Benzinga reports. They presently have a $9.00 target price on the stock. A number of other research analysts have also recently weighed in on the company. HC Wainwright assumed coverage […]
Kairos Pharma (NYSEAMERICAN:KAPA – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a report released on Wednesday,Benzinga reports. They presently have a $9.00 target price on the stock. A number of other research analysts have also recently weighed in on the company. HC Wainwright assumed coverage […]
